Literature DB >> 28891136

Helicobacter pylori infection and nonmalignant diseases.

Olga Sjomina1,2, Frederic Heluwaert3, Driffa Moussata4, Marcis Leja1,2,5.   

Abstract

A substantial decrease in Helicobacter pylori-associated peptic ulcer disease has been observed during the last decades. Drug-related ulcers as well as idiopathic ulcers are becoming predominant and are more refractory to treatment; however, H. pylori infection still plays an important role in ulcer bleeding and recurrence after therapy. The effect of H. pylori eradication upon functional dyspepsia symptoms has been reviewed in this article and generally confirms the results of previous meta-analyses. Additional evidence suggests a lack of impact upon the quality of life, in spite of improvement in symptoms. The association of H. pylori with gastroesophageal reflux disease and Barrett's esophagus remains controversial with a majority of published studies showing a negative association. Furthermore, a strong inverse relationship between the presence of H. pylori and the esophageal eosinophilia was also reported. Several studies and a review addressed the role of H. pylori in autoimmune gastritis and pernicious anemia. The association of the above still remains controversial. Finally, the necessity of routine endoscopy and H. pylori eradication before bariatric surgery is discussed. Several studies suggest the rationale of preoperative upper endoscopy and H. pylori eradication prior to surgery. However, the prevalence of H. pylori infection prior to surgery in these studies generally reflects the overall prevalence of the infection in the particular geographic area. In addition, results on the role of H. pylori in developing postoperative complications remain controversial.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmune gastritis; bariatric surgery; dyspepsia; gastroesophageal reflux disease; peptic ulcer

Mesh:

Year:  2017        PMID: 28891136     DOI: 10.1111/hel.12408

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  7 in total

1.  Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.

Authors:  Hassan Seddik; Hanae Boutallaka; Ilham Elkoti; Fouad Nejjari; Reda Berraida; Sanaa Berrag; Khaoula Loubaris; Sara Sentissi; Ahmed Benkirane
Journal:  Eur J Clin Pharmacol       Date:  2019-01-29       Impact factor: 2.953

2.  Prevalence of gastroesophageal reflux disease: a population-based cross-sectional study in southern Chile.

Authors:  Carlos Manterola; Luis Grande; Luis Bustos; Tamara Otzen
Journal:  Gastroenterol Rep (Oxf)       Date:  2020-02-19

3.  Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.

Authors:  Sho Suzuki; Takuji Gotoda; Chika Kusano; Hisatomo Ikehara; Ryoji Ichijima; Motoki Ohyauchi; Hirotaka Ito; Masashi Kawamura; Yohei Ogata; Masahiko Ohtaka; Moriyasu Nakahara; Koichi Kawabe
Journal:  Gut       Date:  2020-01-08       Impact factor: 23.059

4.  Helicobacter pylori and gastrointestinal and neurological diseases: Study protocol of an umbrella review of systematic reviews and meta-analyses.

Authors:  Baoning Wang; Jing Zhang; Sihan Chen; Mingjiang Bie
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

5.  Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial.

Authors:  Nooshin Naghibzadeh; Fatemeh Salmani; Samira Nomiri; Tahmine Tavakoli
Journal:  BMC Gastroenterol       Date:  2022-03-07       Impact factor: 3.067

6.  Observation of the Gut Microbiota Profile in BALB/c Mice Induced by Plasmodium yoelii 17XL Infection.

Authors:  Wei Guan; Xiaonan Song; Shuguo Yang; Huiyin Zhu; Fang Li; Jian Li
Journal:  Front Microbiol       Date:  2022-03-31       Impact factor: 5.640

7.  Contribution of genetic amplification by PCR for the diagnosis of Helicobacter pylori infection in patients receiving proton pump inhibitors.

Authors:  Thomas Bazin; Arouna Nchare Mfondi; Catherine Julie; Jean-François Émile; Josette Raymond; Dominique Lamarque
Journal:  United European Gastroenterol J       Date:  2018-06-27       Impact factor: 4.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.